m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05348
 [1]
Non-coding RNA Circ_CTNNB1 RBM15  lncRNA       miRNA   circRNA Direct Enhancement m6A modification GPI GPI RBM15 Methylation : m6A sites
m6A Modification:
m6A Regulator RNA-binding motif protein 15 (RBM15) WRITER
 Regulator Info 
m6A Target Glucose-6-phosphate isomerase (GPI)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_CTNNB1 circRNA View Details
Regulated Target RNA binding motif protein 15 (RBM15) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary Circ_CTNNB1 interacted with RBM15 and subsequently promoted the expression of HK2, Glucose-6-phosphate isomerase (GPI) and PGK1 through N6-methyladenosine (m6A) modification to facilitate the glycolysis process and activate OS progression.
Responsed Disease Osteosarcoma ICD-11: 2B51
 Disease Info 
In-vivo Model For in vivo tumour growth studies, 143B cells were subcutaneously injected into the dorsal flanks of 5-week-old male BALB/c nude mice (n = 5 per group) in a blind, randomized fashion. The growth and weight of xenografts were detected 1 month later. In experimental metastasis studies, tail vein injection of 143B cells was performed in a blind, randomized fashion in 5-week-old male BALB/c nude mice (n = 5 per group). Metastasis counts and survival time of each mouse were monitored and recorded, and the xenografts were studied by haematoxylin and eosin (H&E) staining.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2B51: Osteosarcoma 12 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Cisplatin Approved [2]
Synonyms
Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)
    Click to Show/Hide
External Link
CID: 5702198
TTD: D0U5HU
 Compound Name Naxitamab Phase 2 [2]
External Link
TTD: D0HI5D
 Compound Name Tideglusib Phase 2 [3]
Synonyms
NP-031112; NP-12; NP031112; Tideglusib(NP-031112)
    Click to Show/Hide
External Link
CID: 11313622
TTD: D0UT7X
DrugBank: DB12129
 Compound Name Hu3F8 mAb Phase 2 [4]
External Link
TTD: D0R4UA
 Compound Name Saracatinib Phase 2 [5]
Synonyms
H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine
    Click to Show/Hide
External Link
CID: 10302451
TTD: D0M0XB
DrugBank: DB11805
 Compound Name ALMB-0168 Phase 1/2 [6]
External Link
TTD: DXAI94
 Compound Name AU101 Phase 1/2 [7]
External Link
TTD: D0T9JW
 Compound Name [153Sm]CycloSam Phase 1 [8]
External Link
TTD: D8W1DJ
 Compound Name GD2 T cells Phase 1 [9]
External Link
TTD: D0QB7N
 Compound Name Anti-GD2-CAR engineered T cells Phase 1 [10]
External Link
TTD: D09DND
 Compound Name Robatumumab Discontinued in Phase 2 [11]
External Link
TTD: D0X9RN
 Compound Name DG-8 Investigative [12]
Synonyms
DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences
    Click to Show/Hide
External Link
TTD: D0L3VC
References
Ref 1 Circ-CTNNB1 drives aerobic glycolysis and osteosarcoma progression via m6A modification through interacting with RBM15. Cell Prolif. 2023 Jan;56(1):e13344. doi: 10.1111/cpr.13344. Epub 2022 Oct 1.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Evidence for irreversible inhibition of glycogen synthase kinase-3Beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904. doi: 10.1074/jbc.M111.306472. Epub 2011 Nov 18.
Ref 4 ClinicalTrials.gov (NCT02502786) Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma.
Ref 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7731).
Ref 6 ClinicalTrials.gov (NCT04886765) A Phase I/II, Multi-center, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma. U.S.National Institutes of Health.
Ref 7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 8 ClinicalTrials.gov (NCT03612466) A Dose Finding Study of CycloSam Combined With External Beam Radiotherapy. U.S. National Institutes of Health.
Ref 9 ClinicalTrials.gov (NCT01953900) iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
Ref 10 ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Ref 11 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027277)
Ref 12 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.